NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD
L’analyse réalisée dans le cadre de l’étude VAMOS met en évidence le lien entre l’excès de graisse viscérale abdominale et la diminution de la qualité...
Mentions: TH.CA
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist...
Mentions: TH.CA
Mentions: TH.CA
We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to take a look at where Lumen Technologies, Inc. (NYSE:LUMN) stands against other promising penny stocks. Solus’ Dan Greenhaus, and Invesco’s Brian Levitt together appeared on CNBC’s ‘Closing Bell’ on April 15 to talk […]
We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Match Group, Inc. (NASDAQ:MTCH) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]
We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Northern Oil and Gas, Inc. (NYSE:NOG) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide […]
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where SurgePays, Inc. (NASDAQ:SURG) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was characterized […]
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where TuHURA Biosciences, Inc. (NASDAQ:HURA) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Microbot Medical Inc. (NASDAQ:MBOT) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Integra Resources Corp. (NYSEAMERICAN:ITRG) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Satixfy Communications Ltd. (NYSEAMERICAN:SATX) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
MONTRÉAL, 15 avr. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société...
Mentions: TH.CA
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage...
Mentions: TH.CA
RBC Capital analyst Scott Hanold lowered the firm’s price target on Matador (MTDR) to $62 from $70 and keeps an Outperform rating on the shares. The company is confident in its financial position and believes market disruptions provide long-term opportunities, the analyst tells investors in a research note. RBC adds that it does not expect the company to reduce its current activity pace unless WTI oil prices fall sustainably below $60 per barrel. Published first on TheFly – the ultimate source f
RBC Capital lowered the firm’s price target on Chord Energy (CHRD) to $145 from $165 and keeps an Outperform rating on the shares. A sustained sub-$60 per barrel WTI oil price could result in modestly lower activity, though the firm expects the management to continue leaning in assertively to stock buybacks given weakness in the stock, putting shareholder returns at about 100% near-term, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time
RBC Capital lowered the firm’s price target on TD Synnex (SNX) to $145 from $165 and keeps an Outperform rating on the shares after its Investor Day presentation featuring medium-term targets. The firm has reduced its price target to reflect near-term uncertainty and FY25 guidance but also believes that TD Synnex is well positioned to grow above market over the mid-term, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving b
D. Boral Capital analyst Jason Kolbert downgraded Scilex (SCLX) to Hold from Buy after the company announced a 1-for-35 reverse stock split, effective April 15. While the firm recognizes the reverse split as a necessary step to maintain the company’s Nasdaq listing, it is moving to the sidelines pending greater clarity on the company’s next steps and says it will “revisit our stance once the split is implemented and implications for valuation and capital structure become more transparent.” Publi
MONTRÉAL, 11 avr. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société...
Mentions: TH.CA
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage...
Mentions: TH.CA
Mentions: TH.CA
We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where PureCycle Technologies, Inc. (NASDAQ:PCT) stands against Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If companies are […]
Future Pak’s proposal offers a cash consideration of $3.51 to $4.50 per share, implying a premium of 164% to 238% on Theratechnologies’ closing price of $1.33 on Thursday.
La FDA approuve EGRIFTA WRMC (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le...
Mentions: TH.CA
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million,...
Mentions: TH.CA
Mentions: TH.CA
FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows...
Mentions: TH.CA
Mentions: TH.CA